Brief: Kingspan H1 trading profit +10%, pauses buybacks to appraise development pipeline
BRIEF-Kingspan H1 trading profit +10%, pauses buybacks to appraise development pipeline Aug 7 (Reuters) - Kingspan Group PLC KSP.I:
KINGSPAN: INTERIM DIVIDEND OF 27.1 CENT PER SHARE (H1 2025: 26.3 CENT PER SHARE), €650M SHARE BUYBACK PROGRAMME PAUSED 'TO PRESERVE DRY POWDER'
KINGSPAN: H1 REVENUE +8% Y/Y TO €4.86BN (+9% PRE-CURRENCY), EBITDA UP 9% TO €626M
KINGSPAN: H1 TRADING PROFIT +10% Y/Y TO €487.2M, DESPITE CURRENCY HEADWIND OF €8.4M AND ADVNSYS IPO EXPLORATION COSTS OF €4.5M (+13% BEFORE BOTH)
KINGSPAN: SALES IN ADVNSYS +34% (+36% PRE-CURRENCY) BUOYED BY TECH SECTOR ACTIVITY WITH RAPIDLY GROWING MOMENTUM AND BACKLOG
KINGSPAN: INVESTED A TOTAL OF €233.6M IN H1, €155.9M OF THIS WAS ORGANIC CAPEX, NEW FACILITIES BEING BUILT OR COMMISSIONED IN TEXAS, KENTUCKY, VIETNAM, AUSTRALIA.
KINGSPAN: WE CAN REASONABLY EXPECT TO BREAK THROUGH €10BN IN FY REVENUE FOR FIRST TIME, EXPECT FY TRADING PROFIT +18% TO €1.125 BILLION
KINGSPAN: ADVNSYS ORDER INTAKE, BACKLOG MORE THAN DOUBLED Y/Y; TECH SECTOR BLASTING FORWARD, FULLY DETACHED FROM REGULAR ECONOMY AND NORMAL BUILDING ACTIVITY
Further company coverage: KSP.I
(Reporting By Padraic Halpin)
((Padraic.Halpin@thomsonreuters.com;))
Recent news on Kingspan
See all newsEurope Research Roundup: Allianz, Mercedes-Benz, Tesco
Kingspan hit with €40 million EU fine for misleading data on Slovenian deal (updated)
Kingspan hit with €40 million EU fine for misleading data on Slovenian deal
Europe Research Roundup: AstraZeneca, GSK, Kingspan Group
Europe Research Roundup: Hemnet, Polypeptide Group, UMG